Yair Einhorn(@yaireinhorn) 's Twitter Profileg
Yair Einhorn

@yaireinhorn

#Science & #Innovation. Special interest in #BioTech, #GeneEditing, #EpiGeneticEditing, #GeneTherapy 🧬 #CRISPR & #Ophthalmology. #Markets & #Stocks 📈

ID:1238780417324580867

calendar_today14-03-2020 10:54:12

6,9K Tweets

6,4K Followers

39 Following

Yair Einhorn(@yaireinhorn) 's Twitter Profile Photo

This unbelievable graph, made by - Bloomberg, shows just how powerful the Big moguls - $AAPL $GOOG $META and others have become - as so much of our everyday online interactions are owned & operated by this small group of tech moguls. According to this graph…

This unbelievable graph, made by #Bloomberg - @business, shows just how powerful the Big #Tech moguls - $AAPL $GOOG $META and others have become - as so much of our everyday online interactions are owned & operated by this small group of tech moguls. According to this graph…
account_circle
Yair Einhorn(@yaireinhorn) 's Twitter Profile Photo

This unbelievable graph, made by - Bloomberg, shows just how powerful the Big moguls - $AAPL $GOOG $META and others have become - as so much of our everyday online interactions are owned & operated by this small group of tech moguls. According to this graph…

This unbelievable graph, made by #Bloomberg - @business, shows just how powerful the Big #Tech moguls - $AAPL $GOOG $META and others have become - as so much of our everyday online interactions are owned & operated by this small group of tech moguls. According to this graph…
account_circle
Yair Einhorn(@yaireinhorn) 's Twitter Profile Photo

1/Intellia Therapeutics & $REGN announced an expanded collaboration to develop in vivo -based therapies focused on neurological & muscular diseases which will combine $NTLA proprietary Nme2Cas9 platform & Regeneron viral vector delivery technologies. $XBI

1/@intelliatx & $REGN announced an expanded collaboration to develop in vivo #CRISPR-based #GeneEditing therapies focused on neurological & muscular diseases which will combine $NTLA proprietary Nme2Cas9 platform & @Regeneron viral vector delivery technologies. #BioTech $XBI
account_circle
Yair Einhorn(@yaireinhorn) 's Twitter Profile Photo

1/SparingVision has announced positive initial safety data from its Phase I/II PRODYGY clinical trial of SPVN06-a gene-agnostic aimed to stop/slow the disease progression of - one of the leading inherited causes of blindness.  $XBI $NTLA

1/@SparingVision has announced positive initial safety data from its Phase I/II PRODYGY clinical trial of SPVN06-a gene-agnostic #GeneTheapy aimed to stop/slow the disease progression of #RetinitisPigmentosa - one of the leading inherited causes of blindness. #BioTech $XBI $NTLA
account_circle